The stock of Mylan NV (NASDAQ:MYL) is a huge mover today! About 4.09 million shares traded hands. Mylan NV (NASDAQ:MYL) has declined 17.73% since March 4, 2016 and is downtrending. It has underperformed by 25.77% the S&P500.
The move comes after 7 months negative chart setup for the $19.18 billion company. It was reported on Oct, 7 by Barchart.com. We have $34.06 PT which if reached, will make NASDAQ:MYL worth $959.00 million less.
Analysts await Mylan NV (NASDAQ:MYL) to report earnings on November, 4. They expect $1.60 earnings per share, up 11.89% or $0.17 from last year’s $1.43 per share. MYL’s profit will be $856.01 million for 5.60 P/E if the $1.60 EPS becomes a reality. After $1.16 actual earnings per share reported by Mylan NV for the previous quarter, Wall Street now forecasts 37.93% EPS growth.
Mylan NV (NASDAQ:MYL) Ratings Coverage
Out of 13 analysts covering Mylan Inc. (NASDAQ:MYL), 7 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 54% are positive. Mylan Inc. has been the topic of 24 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm earned “Overweight” rating on Wednesday, November 18 by JP Morgan. The firm has “Hold” rating by Zacks given on Thursday, August 27. Deutsche Bank maintained the stock with “Buy” rating in Tuesday, July 28 report. The stock of Mylan NV (NASDAQ:MYL) has “Market Perform” rating given on Monday, July 27 by Cowen & Co. The company was downgraded on Monday, August 17 by Zacks. The firm has “Outperform” rating given on Wednesday, May 4 by Leerink Swann. Leerink Swann maintained it with “Outperform” rating and $55 target price in Monday, August 15 report. The firm has “Equal Weight” rating by Barclays Capital given on Monday, September 21. Leerink Swann maintained the stock with “Outperform” rating in Saturday, August 29 report. Deutsche Bank maintained Mylan NV (NASDAQ:MYL) on Friday, August 7 with “Buy” rating.
According to Zacks Investment Research, “Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.”
Insitutional Activity: The institutional sentiment decreased to 0.45 in 2016 Q2. Its down 0.05, from 0.5 in 2016Q1. The ratio dropped, as 6 funds sold all Mylan NV shares owned while 5 reduced positions. 1 funds bought stakes while 4 increased positions. They now own 533,685 shares or 37.96% less from 860,251 shares in 2016Q1.
The Massachusetts-based Amer Research & Mngmt has invested 0.03% in Mylan NV (NASDAQ:MYL). Westport Resource, a Connecticut-based fund reported 26,765 shares. Novare Mngmt Limited Liability Company reported 79,851 shares or 0.93% of all its holdings. Vantage Inv Limited Liability Company last reported 712 shares in the company. Jacobs & Ca holds 7,305 shares or 0.07% of its portfolio. Gulf Int Bank & Trust (Uk) Limited, a United Kingdom-based fund reported 123,183 shares. The Colorado-based Icon Advisers Inc has invested 0.1% in Mylan NV (NASDAQ:MYL). Eagle Asset accumulated 0.02% or 56,209 shares. Gemmer Asset Mgmt Ltd Limited Liability Company holds 21 shares or 0% of its portfolio. Moreover, Princeton Port Strategies Grp Limited Liability Company has 1.89% invested in Mylan NV (NASDAQ:MYL) for 135,477 shares. Covington Cap Management has 0.16% invested in the company for 39,339 shares. Ntv Asset Management Llc holds 0.26% of its portfolio in Mylan NV (NASDAQ:MYL) for 15,990 shares.
More notable recent Mylan NV (NASDAQ:MYL) news were published by: Prnewswire.com which released: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 06, 2016, also Profitconfidential.com with their article: “Mylan NV: MYL Stock Chart Has Ominous Implications” published on October 04, 2016, Bloomberg.com published: “Mylan Accused by U.S. of Overcharging Medicaid for EpiPen” on October 05, 2016. More interesting news about Mylan NV (NASDAQ:MYL) were released by: Prnewswire.com and their article: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” published on October 06, 2016 as well as Wsj.com‘s news article titled: “Mylan’s EpiPen Pretax Profits 60% Higher Than Number Told to Congress” with publication date: September 26, 2016.
MYL Company Profile
Mylan N.V., incorporated on July 7, 2014, is a global pharmaceutical company. The Firm develops, licenses, makes, markets and distributes generic, branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). The Firm operates through two divisions: Generics and Specialty. The principal markets for Generics are pharmaceutical wholesalers and distributors; group purchasing organizations; drug store chains; independent pharmacies; drug manufacturers; institutions, and public and governmental agencies primarily within the United States and Canada (collectively, North America); Europe, and India, Australia, Japan, New Zealand and Brazil (collectively, Rest of World). The Generics segment also focuses on developing API with non-infringing processes for both internal use and to partner with manufacturers in regulated markets, such as the United States and the European Union at market formation. The principal market for Specialty is pharmaceutical wholesalers and distributors, pharmacies and healthcare institutions primarily in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.